Proteon Therapeutics (NASDAQ: PRTO) is one of 283 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Proteon Therapeutics to related companies based on the strength of its profitability, institutional ownership, analyst recommendations, dividends, valuation, risk and earnings.
Risk and Volatility
Proteon Therapeutics has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500. Comparatively, Proteon Therapeutics’ rivals have a beta of 0.33, meaning that their average share price is 67% less volatile than the S&P 500.
This table compares Proteon Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Proteon Therapeutics||$2.95 million||-$28.52 million||-0.86|
|Proteon Therapeutics Competitors||$286.20 million||$34.74 million||137.20|
Proteon Therapeutics’ rivals have higher revenue and earnings than Proteon Therapeutics. Proteon Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
49.9% of Proteon Therapeutics shares are held by institutional investors. Comparatively, 49.8% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 36.3% of Proteon Therapeutics shares are held by insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This is a summary of recent recommendations for Proteon Therapeutics and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Proteon Therapeutics Competitors||804||3164||11461||230||2.71|
Proteon Therapeutics currently has a consensus target price of $6.86, indicating a potential upside of 261.05%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.86%. Given Proteon Therapeutics’ higher probable upside, analysts plainly believe Proteon Therapeutics is more favorable than its rivals.
This table compares Proteon Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Proteon Therapeutics Competitors||-5,288.04%||-479.11%||-39.96%|
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of vonapanitase in patients undergoing creation of an arteriovenous fistula (AVF). The Company initiated the first of two Phase III trials, PATENCY-1, for vonapanitase in radiocephalic AVFs. Its vonapanitase product candidate is a recombinant human elastase under development as a treatment to prevent AVF and arteriovenous graft (AVG) patency loss.
Receive News & Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.